Advances in the Treatment of Multiple Myeloma: Highlights from ASH 2023 and Beyond - Episode 12
GPRC5D-Targeting Bispecifics in Multiple Myeloma
The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.
The discussion focuses on GPRC5D as an emerging target in multiple myeloma. Early data with the GPRC5D-targeted bispecific antibody talquetamab demonstrates response rates around 60% to 65%. However, progression-free survival appears shorter than with B-cell maturation antigen–directed therapies.
A key toxicity is on-target, off-tumor effects causing dysgeusia and weight loss. This impacts quality of life significantly. Dose reductions or schedule adjustments (eg, biweekly vs weekly dosing) may mitigate these adverse effects. Ongoing trials are also evaluating talquetamab combinations, like with pomalidomide to improve efficacy or with daratumumab, which allows extended talquetamab dosing intervals. Such combinations can overcome high-risk disease. Further follow-up is needed.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.